Drug Approval & Reimbursement in 2023

• Japan Approves Label Expansions for Rexulti, Rituxan, and More
  December 25, 2023

• Leqembi to Cost 2.98 Million Yen per Year, Re-Pricing Might Be Triggered on Patient Upswing
  December 14, 2023

• Shionogi’s Novel Antibiotic Fetroja Gets Fast-Track Listing for Dec. 20
  December 14, 2023

• Leqembi OK’ed for Listing on Dec. 20; Peak Sales Put at 98.6 Billion Yen
  December 13, 2023

• Japan Approves Meiji’s COVID Vaccine, Daiichi Sankyo’s XBB-Tailored Jab
  November 28, 2023

• Japan Approves Label Expansions for Opdivo, Adcetris, and More
  November 27, 2023

• 1st G-Lasta Biosimilar Gets Japan Listing, Stelara Follow-On Not on Roster
  November 21, 2023

• Listing OK’ed for Phesgo, Leqvio, Epkinly, and More; 30 Billion-Plus Yen Peak Sales for 3 Meds
  November 16, 2023

• Wegovy Lands Reimbursement Listing in Japan 8 Months after Approval
  November 16, 2023

• Japan Approves Multiple Firsts, Leqembi, Arexvy, Leqvio, and More
  September 26, 2023

• Japan Approves Eisai/Biogen’s Alzheimer’s Drug Leqembi
  September 25, 2023

• Moderna’s Omicron XBB.1.5 Vaccine Snags Japan Approval
  September 12, 2023

• Japan Approves Pfizer’s Omicron XBB.1.5 Vaccine, Moderna’s Still under Review
  September 4, 2023

• Chuikyo OKs Listing of Litfulo and More; 10 Billion-Plus Yen Peak Sales for Pfizer, Sobi Meds
  August 24, 2023

• Luxturna Priced at 49.6 Million Yen per Vial, Peak Sales Put at 500 Million Yen with 5 Patients
  August 24, 2023

• Japan Approves Enhertu’s NSCLC Use, More Label Expansions
  August 24, 2023

• Japan OKs 1st Homemade COVID Jab, but No Supply Planned; Daiichi to Pursue XBB.1 Update
  August 3, 2023

• Japan Approves Gilead’s HIV Med Sunlenca, Listing Set for Aug. 9
  August 2, 2023

• Japan OKs Oncaspar, Lytgobi, Litfulo, Rinvoq/Keytruda Label Expansions and More
  June 27, 2023

• Japan Approves Novartis’ Gene Therapy Luxturna for Rare Eye Disease
  June 27, 2023

ページ